Duligotuzumab (MEHD-7945A; RG 7597) 是人源化的 IgG-κ 单克隆抗体，特异性靶向 Her3 (ErbB3)。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-EGFR & HER3 Reference Antibody (Duligotuzumab) is 144.47 kDa.

Anti-EGFR & HER3 Reference Antibody (Duligotuzumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-EGFR & HER3 Reference Antibody (Duligotuzumab (USAN)) is 100%, determined by SEC-HPLC.

Duligotuzumab bound to EGFR protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Duligotuzumab bound to Human EGFR-his, and the EC50 was 0.002 nM.

Duligotuzumab bound to HER3 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Duligotuzumab bound to Human-HER3-his, and the EC50 was 0.002 nM.

Duligotuzumab bound to EGFR-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Duligotuzumab bound to EGFR-CHO-K cells, and the EC50 was 0.937 nM.

Duligotuzumab bound to 0920-13 Hu-HER3-FL-HEK293-A4 cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Duligotuzumab bound to 0920-13 Hu-HER3-FL-HEK293-A4 cells, and the EC50 was 0.645 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.